LLS Light the Night Names Cosgrove National Ambassador
The Leukemia & Lymphoma Society has named actress and musician Miranda Cosgrove the National Ambassador for the charity's very popular and successful fundraising campaign 'Light the Night'.
"School of Rock" put her on the map
Miranda Cosgrove, 19, first came to fame after appearing in the film School of Rock. She later had a supporting role in the Nickelodeon sitcom Drake & Josh before getting a show of her own, iCarly, which made her one of the highest paid child actors in Hollywood.
About 'Light the Night'
'Light the Night' is the largest such charity walk of its kind, involving over 250,000 participants every year. It requires little more than an evening stroll in over 200 communities in North America every fall.
Nancy L. Klein, LLS's chief marketing and revenue officer, gave her enthusiastic support for Cosgrove:
"Miranda Cosgrove is an extremely talented and popular young star and we are so grateful that she is giving her time and energy to support The Leukemia & Lymphoma Society's Light The Night Walk… LLS is funding the most promising blood cancer research around the world and with the support of participants in campaigns such as Light The Night we are beating cancer."
You can see Cosgrove's PSA HERE.
Source: LLS
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
